Although the primary effect of TGF-β signaling characterized in this study is the enhanced production of EVs, we also sought to explore possible effects of the compounds that blocked the release of EV+ TGF−β1 from tumor cells in the context of doxorubicin (Dox) or paclitaxel (taxol) cytotoxicity. Here, TGFB1 is linked to neoplasm.